Elevated expression of transforming growth factor-β in adipose tissue from obese mice

Molecular Medicine

Volumn 3, Issue 1, 1997, Pages 37-48

  Samad, Fahumiya ^a   Yamamoto, Koji ^a   Pandey, Manjula ^a   Loskutoff, David J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CELL STRAIN 3T3; CONTROLLED STUDY; GENE EXPRESSION; IN SITU HYBRIDIZATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION;

EID: 0031000588     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401666     Document Type: Article

References (55)

1. Larsson B. (1991) Obesity, fat distribution and cardiovascular disease. Int. J. Obesity 15: 53-57.
2. Björntorp P. (1992) Abdominal fat distribution and disease: An overview of epidemiological data. Ann. Med. 24: 15-18.
3. DeFronzo RA, Ferrannini E. (1991) Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194.
4. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. (1994) Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43: 104-109.
5. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. (1993) The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42: 945-949.
6. Legnani C, Maccaferri M, Tonini P, Cassio A, Cacciari E, Coccheri S. (1988) Reduced fibrinolytic response in obese children: Association with high baseline activity of the fast acting plasminogen activator inhibitor (PAI-1). Fibrinolysis 2: 211-214.
7. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Allan C. (1989) Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 38: 913-915.
8. Sprengers ED, Kluft C. (1987) Plasminogen activator inhibitors. Blood 69: 381-387.
9. Loskutoff DJ. (1988) Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy. Semin. Thromb. Hemost. 14: 100-109.
10. Schneiderman J, Loskutoff DJ. (1991) Plasminogen activator inhibitors. Trends Cardiovasc. Med. 1: 99-102.
11. Primrose JN, Davies JA, Prentice CRM, Hughes R, Johnston D. (1992) Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb. Haemost. 68: 396-399.
12. Samad F, Loskutoff DJ. (1996) Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol. Med. 2: 568-582.
13. Hotamisligil GS, Shargill NS, Spiegelman BM. (1993) Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 259: 87-91.
14. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. (1995) Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
15. van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ. (1988) Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72: 1467-1473.
16. Kooistra T. (1990) The use of cultured human endothelial cells and hepatocytes as an in vitro model system to study modulation of endogenous fibrinolysis. Fibrinolysis 4: 33-39.
17. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. (1986) Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35: 250-253.
18. Mykkänen L, Rönnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M. (1994) Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler. Thromb. 14: 1264-1271.
19. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. (1993) Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: Studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 36: 817-825.
20. Samad F, Yamamoto K, Loskutoff DJ. (1996) Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: Induction by tumor necrosis factor-α and lipopolysaccharide. J. Clin. Invest. 97: 37-46.
21. Sawdey MS, Loskutoff DJ. (1991) Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J. Clin. Invest. 88: 1346-1353.
22. Schleef RR, Sinha M, Loskutoff DJ. (1985) Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator. J. Lab. Clin. Med. 106: 408-415.
23. Wang AM, Doyle MV, Mark DF. (1989) Quantitation of mRNA by the polymerase chain reaction. Proc. Natl. Acad. Sci. U.S.A. 86: 9717-9721.
24. Yamamoto K, Loskutoff DJ. (1996) Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J. Clin. Invest. 97: 2440-2451.
25. Vanden Heuvel JP, Tyson FL, Bell DA. (1993) Construction of recombinant RNA templates for use as internal standards in quantitative RT-PCR. BioTechniques 14: 395-398.
26. Keeton M, Eguchi Y, Sawdey M, Ahn C, Loskutoff DJ. (1993) Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am. J. Pathol. 142: 59-70.
27. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew SB, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. (1986) Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163: 1037-1050.
28. Rodbell M. (1964) Metabolism of isolated fat cells: I. Effects of hormones on glucose metabolism and lipolysis. J. Biol. Chem. 239: 375-380.
29. Moore DD. (1996) Preparation of genomic DNA from mammalian tissue. In: Ausubel FM, Brent R, Kingston RE, et al. (eds) Current Protocols in Molecular Biology. John Wiley and Sons, New York, Vol. 1, pp. 221-222.
30. Green H, Kehinde O. (1975) An established preadipose cell line and its differentiation in culture: II. Factors affecting the adipose conversion. Cell 5: 19-27.
31. Markman B. (1989) Anatomy and physiology of adipose tissue. Clin. Plast. Surg. 16: 235-243.
32. McCartney-Francis NL, Wahl SM. (1994) Transforming growth factor beta: A matter of life and death. J. Leukocyte Biol. 55: 401-409.
33. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B. (1987) Some recent advances in the chemistry and biology of transforming growth factor-β. J. Cell Biol. 105: 1039-1045.
34. Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, Ross R, Sporn MB. (1987) Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc. Natl. Acad. Sci. U.S.A. 84: 6020-6024.
35. Sawdey M, Podor TJ, Loskutoff DJ. (1989) Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells: Induction by transforming growth factor-β, lipopolysaccharide, and tumor necrosis factor-α. J. Biol. Chem. 264: 10396-10401.
36. Reilly CF, McFall RC. (1991) Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J. Biol. Chem. 266: 9419-9427.
37. Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela O, Blasi F, Dano K. (1987) Transforming growth factor-β is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J. 6: 1281-1286.
38. Thalacker FW, Nilsen-Hamilton M. (1987) Specific induction of secreted proteins by transforming growth factor-β and 12-0-tetradecanoylphorbol-13-acetate. Relationship with an inhibitor of plasminogen activator. J. Biol. Chem. 262: 2283-2290.
39. Westerhausen DR, Hopkins WE, Billadello JJ. (1991) Multiple transforming growth factor-β-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. J. Biol. Chem. 266: 1092-1100.
40. Fujii S, Sobel BE. (1990) Induction of plasminogen activator inhibitor by products released from platelets. Circulation 82: 1485-1493.
41. Herberg L, Coleman DL. (1977) Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 26: 59-99.
42. Pekary AE, Berg L, Wang J, Lee P, Dubinett SM, Hershman JM. (1995) TNF-alpha, TSH, and aging regulate TGF-beta synthesis and secretion in FRTL-5 rat thyroid cells. Am. J. Physiol. 268: R808-R815.
43. Moses HL, Yang EY, Pietenpol JA. (1990) TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights. Cell 63: 245-247.
44. Moses HL, Coffey Jr RJ, Leof EB, Lyons RM, Keski-Oja J. (1987) Transforming growth factor beta regulation of cell proliferation. J. Cell Physiol. 5: 1-7.
45. Bortell R, van Wijnen AJ, Ramsey-Ewing AL, Stein GS, Stein JL. (1992) Differential regulation of H4 histone gene expression in 3T3-L1 pre-adipocytes during arrest of proliferation following contact inhibition or differentiation and its modulation by TGF beta 1. J. Cell. Biochem. 50: 62-72.
46. Jeoung DI, Tang B, Sonenberg M. (1995) Mitogenic response to TGF-beta in 3T3-F442A cells. Biochem. Biophys. Res. Commun. 216: 964-969.
47. Butterwith SC, Goddard C. (1991) Regulation of DNA synthesis in chicken adipocyte precursor cells by insulin-like growth factors, platelet-derived growth factor and transforming growth factor-beta. J. Endocrinol. 131: 203-209.
48. Vassaux G, Negrel R, Ailhaud G, Gaillard D. (1994) Proliferation and differentiation of rat adipose precursor cells in chemically defined medium: Differential action of anti-adipogenic agents. J. Cell. Physiol. 161: 249-256.
49. Pfeiffer A, Schatz H. (1995) Diabetic microvascular complications and growth factors. Exp. Clin. Endocrinol. Diabetes 103: 7-14.
50. Border WA. (1994) Transforming growth factor-beta and the pathogenesis of glomerular diseases. Curr. Opin. Nephrol. Hypertension 3: 54-58.
51. Arrants J. (1994) Hyperinsulinemia and cardiovascular risk. Heart Lung 23: 118-122.
52. Sowers JR. (1992) Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension, and accelerated atherosclerosis. J. Clin. Pharmacol. 32: 529-535.
53. Sharma K, Ziyadeh FN. (1995) Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44: 1139-1146.
54. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. (1996) Elaboration of type-1 plasminogen activator inhibitor from adipocytes: A potential pathogenetic link between obesity and cardiovascular disease. Circulation 93: 106-110.
55. Remacle C, and Gregoire F. (1992) Cellular and molecular biology in the study of the physiopathology of obesity. Acta Glinka Belgica 14: (Suppl.) 3-12.